Abstract
Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.
Lingua originale | English |
---|---|
pagine (da-a) | 607-615 |
Numero di pagine | 9 |
Rivista | Expert Opinion on Pharmacotherapy |
Volume | 16 |
DOI | |
Stato di pubblicazione | Pubblicato - 2015 |
Keywords
- Animals
- Anti-Bacterial Agents
- Diarrhea
- Drug Interactions
- Drug Resistance, Bacterial
- Humans
- Irritable Bowel Syndrome
- Rifamycins
- antibiotics
- gut microbiota
- irritable bowel syndrome
- pharmacokinetic
- rifaximin